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Background: The human dicer1 gene has been predicted to produce several mRNA variants that encode truncated
Dicer1 proteins of varying lengths. One of these Dicer1 variants, Dicer1e, was recently found to be differentially
expressed in breast cancer cells. Because the expression and function of the Dicer1e protein variant has not been
well characterized and the underlying molecular mechanisms for the development of oral squamous cell
carcinomas (OSCCs) are poorly understood, the present study sought to characterize the biological role of Dicer1e
and determine its relationship, if any, to OSCC pathogenesis.
Methods: Western blot analyses were used to examine Dicer1e expression levels in a panel of oral cancer cells/
tissues and during epithelial-mesenchymal transition (EMT), followed by 5′/3′-RACE analyses to obtain the full-length
Dicer1e transcript. Biochemical fractionation and indirect immunofluorescent studies were performed to determine
the cellular localization of Dicer1e and the effects of Dicer1e silencing on cancer cell proliferation, clonogenicity,
and drug sensitivity were also assessed.
Results: Dicer1e protein levels were found to be overexpressed in OSCC cell lines of epithelial phenotype and in
OSCC tissues with its levels downregulated during EMT. Moreover, the Dicer1e protein was observed to
predominantly localize in the nucleus. 5′/3′-RACE analyses confirmed the presence of the Dicer1e transcript and
silencing of Dicer1e impaired both cancer cell proliferation and clonogenicity by inducing either apoptosis and/or
G2/M cell cycle arrest. Lastly, Dicer1e knockdown enhanced the chemosensitivity of oral cancer cells to cisplatin.
Conclusion: The expression levels of Dicer1e influence the pathogenesis of oral cancer cells and alter their
response to chemosensitivity, thus supporting the importance of Dicer1e as a therapeutic target for OSCCs.
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OSCC is a malignant neoplasm of the head and neck re-
gion accounting for over 90% of all subtypes of head and
neck cancers [1]. Cancer of the oral cavity and pharynx
are a significant global burden with an incidence of
400,000 new cases and more than 200,000 deaths world-
wide [2,3]. In the USA they represent 2.5% of the annually
diagnosed malignancies in men [4] and it is estimated that
more than 40,000 Americans will be diagnosed and ap-
proximately 8,000 will die [5]. Despite advances in the
fields of oncology and surgery, the 5-year survival rate for* Correspondence: jakymiw@musc.edu
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unless otherwise stated.all stages is approximately 62% and it has only modestly
improved in the last 30 years [1,5-7]. In order to develop
new therapies for treating oral cancer, new molecular in-
sights into its pathobiology are required.
RNA interference (RNAi) is a post-transcriptional gene
regulatory mechanism that can precisely silence gene
expression [8]. It is activated by exogenous small non-
coding double-stranded RNAs (dsRNAs) or by endo-
genous, small non-coding RNAs known as microRNAs
(miRNAs) [8,9]. Human miRNAs play a regulatory role
in diverse cellular and molecular processes including
protection against viruses, responses to environmental
conditions, cellular proliferation, differentiation, and
apoptosis [10-12]. Because of the modulatory functions
that they perform, it is not unexpected that theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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their biogenesis, are implicated in the pathogenesis of
human diseases such as cancer, fibrosis and immuno-
logic disorders [13-18]. In this regard, it has been well
documented that one of the key enzymes of the RNAi
pathway, Dicer1, has an abnormal expression in dif-
ferent types of cancer, including OSCCs [15,19,20].
Dicer1 is a highly conserved multidomain RNase type
III enzyme that plays an essential role in the RNAi and
miRNA pathways [21,22]. The human dicer1 gene, which
is located on chromosome 14, spans a region of about 71
kbp and comprises 29 exons [23,24]. The gene encodes a
218-kDa protein that is found in almost all eukaryotes
[9,12,25,26]. Dicer1 is responsible for processing dsRNAs
into small interfering RNAs (siRNAs) and precursor miR-
NAs (pre-miRNAs) into mature miRNAs [21,27,28]. The
small non-coding RNAs generated by Dicer1 are typically
between 20-27 nucleotides long [29,30] and they function
as a guide for the RNA-induced silencing complex (RISC)
that targets mRNA for silencing [29,31]. The targeting
of the mRNA occurs through a base-pairing-dependent
mechanism that leads to translational repression or
mRNA degradation [8,32,33].
To date, a number of Dicer1 mRNA variants have been
described; however, all the reported transcripts have been
found to encode the same full-length protein because the
diversity was observed to affect only the length and
composition of either their 3′ or 5′-untranslated regions
[27,34,35]. Recently, the first mRNA splice variant of the
human dicer1 gene bearing a modified coding sequence
was identified in neuroblastoma cells [24]. In fact, the
dicer1 gene has been predicted to produce several mRNA
splice variants in addition to the one found in neuro-
blastoma cells that encode truncated Dicer1 proteins of
varying lengths [23]. One of these Dicer1 mRNA splice
variants termed, Dicer1e, was predicted to translate a 93-
kDa protein which was found to be differentially expressed
between epithelial and mesenchymal breast cancer cells
[36]. Because the expression and function of the Dicer1e
protein variant has not been well characterized and it
currently remains unclear as to its biological and patho-
logical significance, this study sought to examine the
biological role of the Dicer1e protein variant and determine
its relationship, if any, to oral cancer pathogenesis.
Results
Dicer 1e is overexpressed in OSCC cell lines of epithelial
phenotype and in OSCC tissues
The human dicer1 gene is predicted to produce several
mRNA variants bearing modified coding sequences
[23,36], one of which, the 93-kDa Dicer1e protein va-
riant, was reported to be differentially expressed in
epithelial and mesenchymal breast cancer cells [36]. In
order to determine the endogenous expression levels ofDicer1e in oral cancer cells, the expression of the ~93-kDa
Dicer1e protein was examined in a panel of cell lines de-
rived from tongue squamous cell carcinomas (SCCs) and
compared to normal human oral keratinocytes (HOKs) by
Western blot analysis (Figure 1A). Quantitation of the
Dicer1e expression levels demonstrated that the OSCC
cell lines (CAL 27, SCC-4, and SCC-25) of epithelial
phenotype (high E-cadherin and low vimentin expression
levels), exhibited approximately between 2 and 9-fold dif-
ferences in Dicer1e protein levels compared to HOKs,
whereas, OSCC cell lines of mesenchymal phenotype
(high vimentin and low E-cadherin expression levels),
exhibited either equivalent (SCC-15) or slightly reduced
levels of Dicer1e expression (SCC-9, 0.8 fold) (Figure 1B).
Together, these results corroborated the observed diffe-
rential expression of Dicer1e in epithelial and mesenchy-
mal breast cancer cell lines [36]. It is important to note
that the Hinkal et al. study [36] also reported the differen-
tial expression of a 113-kDa Dicer1d protein variant in
epithelial and mesenchymal breast cancer cells. However,
in our analyses we did not detect a 113-kDa protein band
in any of the oral cancer cell lysates. To verify that this
was not due to differences between oral cancer cells and
breast cancer cells, we also compared the Dicer1e migra-
tion patterns to that of the T47D breast cancer cell line
that was similarly used in their study and found only evi-
dence for the expression of the 93-kDa Dicer1e protein
variant (Figure 1A). In addition to our analyses of Dicer1e
protein levels, the expression levels of the 218-kDa Dicer1
protein were also analyzed/quantitated and observed to be
upregulated in OSCC cell lines (Figure 1A and B), as
previously reported [19]. Lower levels of Dicer1 were de-
tected in mesenchymal cells compared with epithelial cells
(Figure 1A and B), which was consistent with several other
studies that have reported that the downregulation of
Dicer1 expression levels also appear to be associated with
epithelial-mesenchymal transition (EMT) [23,36,37].
Having observed a differential expression of Dicer1e in
epithelial and mesenchymal oral cancer cell lines and
knowing that Dicer1e protein levels have been reported
to decrease during EMT using immortalized human epi-
thelial mammary cells [36], we subsequently proceeded
to analyze whether the induction of EMT in oral cancer
cells would similarly affect Dicer1e protein levels. Stimu-
lation of SCC-4 and SCC-25 cells with TGF-β, a known
inducer of EMT in oral cancer cells [38,39], was found
to transition the cells from an epithelial to mesenchymal
phenotype with a concurrent decrease in Dicer1e protein
levels in comparison to unstimulated cells (Figure 1C).
Thus, based on these results, it appeared that Dicer1e
downregulation was associated with EMT.
The aberrant expression of Dicer1e protein observed in
tongue SCC cell lines, prompted us to also examine the
Dicer1e protein expression levels in five human tongue
Figure 1 Dicer1e is overexpressed in human OSCC cell lines of epithelial phenotype and in OSCC tissues. (A) Western blot analysis of
Dicer1 and Dicer1e expression in a panel of human OSCC cell lines (CAL 27, SCC-4, SCC-9, SCC-15 and SCC-25) compared to normal human oral
keratinocytes (HOK). The breast cancer cell line T47D was used as a positive control for Dicer1e protein expression based on the findings from
the Hinkal et al. study [36]. Epithelial and mesenchymal phenotypes were determined by examining the expression of E-cadherin and vimentin.
GAPDH was used as a loading control. The data are representative of three independent experiments. MWM, molecular weight markers (kDa).
(B) Quantitative measurement of the relative fold expression levels of Dicer1 and Dicer1e proteins in oral cancer cell lines compared to HOK. Dicer1 and
Dicer1e protein levels were normalized to GAPDH. Values are expressed as mean ± SEM of three independent experiments. (C) Western blot showing
Dicer1e expression in SCC-4 and SCC-25 cells stimulated for 8 days with TGF-β compared to unstimulated cells. Epithelial-mesenchymal transition was
confirmed by examining the expression of E-cadherin and vimentin. GAPDH was used as a loading control. (D) Western blot analysis of Dicer1 and
Dicer1e protein expression in human adjacent normal (N) and tumor (T) tissues. GAPDH was used as a loading control.
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sistent with our Western blot results for OSCC cell lines of
epithelial phenotype, the ~93-kDa Dicer1e protein levels in
five tissue sets were found to be overexpressed in all tongue
SCC tissues compared with the adjacent normal tissues
(Figure 1D). Additionally, the 218-kDa Dicer1 protein was
also found to be upregulated in 4 of 5 OSCC tissue sam-
ples, thus, corroborating our previous findings that oral
cancer tissues have increased levels of Dicer1 [19]. Of note,
during our analysis of the human tissues, we also detected
a ~75-kDa anti-Dicer1 antibody-reactive protein that was
similarly upregulated in OSCC tissues. However, the iden-
tity of this protein was unclear and remains to be deter-
mined, as it did not correspond to any predicted Dicer1
variants previously reported by the Grelier et al. and Hinkal
et al. studies [23,36]. Nonetheless, these data suggested that
in OSCCs the expression of Dicer1e protein was elevated
compared to normal tissues.
Oral cancer cells express the Dicer1e mRNA variant of the
dicer1 gene
The human dicer1 gene is located on chromosome 14
and spans a region of about 71 kbp and comprises 29
exons [24]. To date, a number of Dicer1 mRNA variantshave been described; however, all the reported tran-
scripts have been found to encode the same full-length
protein [34,35,40]. More recently, however, the first
mRNA splice variant of the human dicer1 gene bearing
a modified coding sequence was identified in neuroblast-
oma cells [24]. In fact, the dicer1 gene has been pre-
dicted to produce 14 mRNA variants in addition to the
one found in neuroblastoma cells, including 3 full-length
forms and 11 mRNA variants that encode truncated
Dicer1 proteins of varying lengths, one being Dicer1e
[23,36]. Although our data, plus the Hinkal et al. study
[36], had confirmed that a ~93-kDa Dicer1 protein
variant was present in cells, no biochemical evidence
existed that this protein variant was the product of a
predicted Dicer1 mRNA variant. As a result, to confirm
that cells expressed the Dicer1e transcript, we performed
5′ and 3′-RACE analyses using mRNA harvested
from SCC-25 cells, a cell line exhibiting one of the high-
est levels of Dicer1e protein expression (Figure 2).
5′-RACE analysis using a reverse primer (Dic1e5AS)
designed to target a unique sequence found only in
Dicer1e resulted in the amplification of a ~380 bp pro-
duct that closely corresponded to the expected 5′-RACE
product size of 373 bp (Figure 2A). Subsequent 3′-
Figure 2 5′ and 3′-RACE analyses confirm the presence of the
Dicer1e transcript. (A) 5′-RACE analysis using a reverse primer
(Dic1e5AS) designed to target a unique sequence found only in
Dicer1e resulted in the amplification of a ~380 bp product that
closely corresponded to the expected 5′-RACE product size of
373 bp. (B) 3′-RACE analysis followed by nested PCR using a forward
primer (Dic1e3S2) designed to target a unique sequence of Dicer1e
resulted in the amplification of a ~2,500 bp product that closely
corresponded to the expected 3′-RACE product size of 2,472 bp.
MWM, molecular weight markers.
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followed by nested PCR using a second forward primer
(Dic1e3S2) designed to target the unique sequence of
Dicer1e resulted in the amplification of a ~2,500 bp
product that also closely corresponded to the expected
3′-RACE product size of 2,472 bp (Figure 2B). Cloning
and complete sequencing of both the 5′ and 3′-RACE
products confirmed the existence of the Dicer1e tran-
script. Of note, RT-PCR analysis was also performed in
an attempt to detect the Dicer1d mRNA variant; how-
ever, no predicted PCR products were observed in either
oral cancer cells or the T47D breast cancer cell line (data
not shown). The absence of this transcript in cells cor-
roborated our Western blot results and most likely ex-
plained why the 113-kDa Dicer1d protein was not
expressed in cells.
The sequence of the complete Dicer1e cDNA and the
predicted amino acid sequence [GenBank: KJ175111] are
shown in Figure 3A. Comparison between the experimen-
tal and the NCBI AceView database (http://www.ncbi.nlm.
nih.gov/IEB/Research/Acembly/) predicted cDNA se-
quences, demonstrated only minor differences in the 5′
and 3′-UTR regions with no alterations to the Dicer1e
protein coding sequence. The Dicer1e transcript consisted
of 2,822 nucleotides that were predicted to encode an 820
amino acid truncated protein form of Dicer1 (~93-kDa)
comprising both RNase III domains, a nuclear localization
signal (NLS) and the dsRNA binding domain (dsRBD)
(Figure 3A and B).Dicer1e is predominantly localized in the nucleus
Based on the NCBI AceView database, PSORT II analysis
(http://psort.hgc.jp/) of the Dicer1e protein sequence
predicts a possible bipartite NLS between amino acids 247
to 264 (KKVSNCNLYRLGKKKGL) and the subcellular
location of Dicer1e protein to be most likely in the nucleus.
Furthermore, a more recent study by Doyle et al. [41] found
that the dsRBD of human Dicer1 functions as a NLS, a
domain that is also present in Dicer1e. Therefore, to investi-
gate the possibility that the Dicer1e protein was localized to
the nucleus, we performed biochemical fractionation studies
using cytoplasmic and nuclear protein extracts obtained
from all the OSCC cell lines and HOKs (Figure 4A). Ana-
lyses of the data demonstrated that Dicer1e was localized to
the nuclear fraction in all cell types examined. No differ-
ences in cellular localization were detected between the oral
cancer cell lines and HOKs. However, in the OSCC cell lines
exhibiting high expression levels of Dicer1e (CAL 27, SCC-
4, and SCC-25), Dicer1e was also detected in the cytoplasm.
Interestingly, the Doyle et al. study [41] found that a C-
terminal fragment of Dicer1 (containing both RNase III
domains plus the dsRBD), a construct structurally similar to
Dicer1e (except that it lacked the N-terminal 210 amino
acids present within the Dicer1e protein sequence), could
localize to the cytoplasm, but failed to localize to the
nucleus of HeLa cells. In an effort to resolve this discre-
pancy and to confirm our observed nuclear localization of
Dicer1e, the localization of a recombinant FLAG-tagged
Dicer1e protein was subsequently tested in transiently trans-
fected HeLa cells (Figure 4B). Indirect immunofluorescent
(IIF) analyses of these transfected cells confirmed nuclear
localization of the recombinant Dicer1e protein (Figure 4B,
upper panels i-iii, arrows), with nuclei verified by DAPI
staining (Figure 4B, lower panels i-iii). Additionally, the
recombinant Dicer1e protein was also found to be either
equally distributed between both nuclear and cytoplasmic
compartments (Figure 4B, upper panels ii and iii, arrow-
heads) or exclusively localized within the cytoplasm of trans-
fected cells (Figure 4B, upper panel iii, double-arrowhead).
Together, these data demonstrated that Dicer1e could
primarily localize to the nucleus in cells, especially in low
Dicer1e expressing cells (HOKs, SCC-9, and SCC-15) with
the ability to also accumulate in the cytoplasm, particularly
in high Dicer1e expressing cells (CAL 27, SCC-4, and SCC-
25) or in transfected HeLa cells overexpressing a recom-
binant form of the Dicer1e protein. Moreover, these data
suggested that the 210 amino acid sequence N-terminal of
the first RNase III domain within Dicer1e appeared to be
important for enabling the nuclear accumulation of Dicer1e.
Depletion of Dicer1e expression inhibits the cell proliferation
and clonogenic potential of oral cancer cell lines
To determine whether the higher levels of Dicer1e contri-
bute to the proliferation and clonogenic potential of oral
Figure 3 (See legend on next page.)
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Figure 3 Human Dicer1e. (A) The Dicer1e cDNA sequence and its deduced amino acid sequence [GenBank: KJ175111]. The largest open reading
frame encodes an 820 amino acid protein with a predicted molecular mass of ~93-kDa. The underlined nucleotides are the upstream in-frame stop
codons, the translational methionine start site, the siDicer1e sense sequence, and the translational stop codon, respectively. The nucleotides in bold
type represent the locations of the Dicer1/1e-specific sense primer (Dic1/1e3S1) and the Dicer1e-specific antisense/sense primers (Dic1e5AS and
Dic1e3S2), respectively. The underlined amino acid residues are the two ribonuclease III (RNase III) domains. The amino acid residues highlighted by a
box are the predicted nuclear localization signal (NLS). The amino acid residues in bold type represent a unique sequence of residues not present in
the Dicer1 protein (Unique) and the double-stranded RNA binding domain (dsRBD), respectively. (B) Schematic representation of human Dicer1
protein in comparison to Dicer1e. Individual protein domain structures are indicated by different shadings. Helicase, ATPase/helicase; DUF283, domain
of unknown function; PAZ, Piwi/Argonaute/Zwille.
Cantini et al. Molecular Cancer 2014, 13:190 Page 6 of 15
http://www.molecular-cancer.com/content/13/1/190cancer cells, we employed siRNA knockdown of Dicer1e
expression. Using an siRNA designed to specifically target
a unique sequence in Dicer1e mRNA (siDicer1e), we found
the Dicer1e protein levels to be considerably reduced (by
at least 80%) compared to cells transiently transfected with
a control non-targeting siRNA (siNT) 48 hours post-
treatment (Figure 5A). Of note, the Dicer1e-silencing effect
was also assessed 7 and 9 days post-transfection and ob-
served to persist up to 9 days, with maximum silencing
occurring 7 days post-transfection for several of the cell
lines (see Additional file 1: Figure S1). To ensure the tar-
geting specificity of siDicer1e, we also analyzed the protein
levels of Dicer1 and found Dicer1 expression to be un-
affected upon treatment with siDicer1e compared to siNT
(Figure 5A and Additional file 1: Figure S1). Having de-
monstrated that siDicer1e was capable of suppressing
Dicer1e protein levels, but not Dicer1, we next examined
the effects of Dicer1e depletion on cancer cell proliferation.
The cell proliferation experiment was carried out where
CAL 27, SCC-4, and SCC-25 cells were either transfectedFigure 4 The cellular localization of Dicer1e protein variant is predom
protein levels in nuclear (N) and cytoplasmic (C) fractions and whole (W) ce
SCC-25) and normal HOKs. The histone deacetylase class 1 (HDAC1) and GA
(B) HeLa cells transiently transfected with FLAG-Dicer1e. Representative image
i-iii). Cells with predominantly nuclear (arrows), nuclear and cytoplasmic (arrow
indicated. Nuclei were counterstained with DAPI (lower panels i-iii). Scale bar:with siNT or siDicer1e, after which cell numbers were
assayed 2, 4, and 7 days post-transfection (Figure 5B). The
growth curves showed that silencing of Dicer1e sig-
nificantly inhibited cell proliferation over a period of 7 days
in all treated oral cancer cell lines compared to control
siNT-transfected cells. Furthermore, consistent with the
cell proliferation assays, in colony formation assays the de-
pletion of Dicer1e in CAL 27, SCC-4, and SCC-25 cells
lead to a significant reduction in foci number compared to
control siNT-treated cells (Figure 5C). Together, these data
demonstrated that the upregulation of Dicer1e was a con-
tributing factor towards the transforming phenotypes of
oral cancer cells.
Silencing of Dicer1e induces either apoptosis and/or cell
cycle arrest in oral cancer cell lines
Because the depletion of Dicer1e had cytostatic effects on
oral cancer cells, we next examined whether this inhi-
bition in cell growth was possibly due to the induction of
apoptosis and/or cell cycle arrest. To first assess the roleinantly nuclear. (A) Western blot analysis of Dicer1 and Dicer1e
ll lysates of human OSCC cell lines (CAL 27, SCC-4, SCC-9, SCC-15, and
PDH were used as nuclear and cytoplasmic markers, respectively.
s are shown of recombinant Dicer1e localization in cells (upper panels
heads), or cytoplasmic (double-arrowheads) Dicer1e localizations are
20 μm.
Figure 5 Knockdown of Dicer1e impairs cell proliferation and clonogenicity of oral cancer cells. (A) Western blot analysis of Dicer1 and
Dicer1e protein levels in human OSCC cell lines (CAL 27, SCC-4, and SCC-25) 48 hours post-transfection with either control non-targeting siRNA (siNT)
or siRNA targeting Dicer1e (siDicer1e). GAPDH was used as a loading control. (B) Cell proliferation assay was performed in OSCC cell lines CAL 27,
SCC-4, and SCC-25, after treatment with siDicer1e compared to control siNT-treated cells. Data are mean ± SEM of three separate experiments
performed in triplicate, where *P < 0.05 compared to siNT treated cells (Student’s t Test). (C) Assessment of clonogenic potentials of the siDicer1e-treated
oral cancer cell lines CAL 27, SCC-4, and SCC-25, compared to control siNT-treated cells. The number of colonies were counted and the data are presented
as mean ± SEM of three separate experiments performed in duplicate, where ****P < 0.0001, *P < 0.05 compared to siNT treated cells (Student’s t Test).
Cantini et al. Molecular Cancer 2014, 13:190 Page 7 of 15
http://www.molecular-cancer.com/content/13/1/190of apoptosis, we transfected CAL 27, SCC-4, and SCC-25
cells with either siNT or siDicer1e, after which the cells
were lysed 48 hours post-transfection and assayed for
several apoptotic makers by Western blot analyses
(Figure 6A). Examination of the different cellular lysates
demonstrated that Dicer1e depletion resulted in a strong
induction of apoptosis in CAL 27 cells, as was evident bythe high levels of cleavage of caspase-3 and poly(ADP-
ribose) polymerase (PARP), two caspase-dependent apop-
totic markers. Very weak or no detectable changes in the
cleavage of PARP and caspase-3 were observed in Dicer1e
depleted SCC-4 and SCC-25 cells, respectively. Because of
the weak or no apoptotic response in Dicer1e depleted
SCC-4 and SCC-25 cells, we next examined whether
Figure 6 Silencing of Dicer1e induces apoptosis and/or G2/M cell cycle arrest in oral cancer cells. (A) Western blot analysis of PARP and
caspase-3 cleavage levels in human OSCC cell lines (CAL 27, SCC-4, and SCC-25) 48 hours post-transfection with either control non-targeting
siRNA (siNT) or siRNA targeting Dicer1e (siDicer1e). Dicer1e and GAPDH levels were monitored to ensure knockdown and equal loading of
samples, respectively. (B) Cell cycle analyses of SCC-4 and SCC-25 cells after treatment with siDicer1e compared to control siNT-treated cells. Data
are mean ± SEM of three independent experiments, where *P < 0.05 compared to siNT treated cells (Student’s t test). (C) Western blot analysis of
p53 protein levels in CAL 27, SCC-4, and SCC-25 cell lines 48 hours post-transfection with either control siNT or siDicer1e. GAPDH was used as a
loading control.
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gression of these two cell lines. Flow cytometry analyses
demonstrated that depletion of Dicer1e in both cell
lines affected their cell cycle distribution. As shown in
Figure 6B, there was an increase in the percentage of cells
in the G2/M phase 48 hours post-transfection with
siDicer1e compared to control siNT-treated cells. More
specifically, the percentage of cells at the G2/M phase sig-
nificantly increased by approximately 13% and 10% in
SCC-4 and SCC-25 cells, respectively. Thus, the aboveresults indicated that suppression of Dicer1e levels in
Dicer1e-overexpressing oral cancer cells could promote
either apoptosis and/or cell cycle arrest.
The observed differences in cellular responses between
these three oral cancer cell lines were most likely due to
their molecular profile differences. For example, it is well
documented that these three cell lines exhibit different
types of mutations of the tumor suppressor protein p53:
in particular, CAL 27 cells have a missense mutation in
codon 193 of exon 6 (A→T transversion) [42,43]; SCC-4
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(C→T transition) [44-46]; and SCC-25 cells have a
frameshift mutation in codon 209 of exon 6 (two base pair
deletion) that results in undetectable levels of p53 protein
within these cells [44,46,47]. Because p53 is a key mole-
cular regulator of apoptosis and cell cycle arrest [48], we
examined the effects of Dicer1e silencing on p53 protein
levels (Figure 6C). Upon silencing of Dicer1e in the diffe-
rent cell lines, it was found that CAL 27 cells that had the
strongest induction levels of apoptosis had a large increase
in p53 protein levels compared to control siNT treated
cells, whereas the Dicer1e-depleted SCC-4 and SCC-25
cells that had either weak or no detectable apoptotic re-
sponses, had a moderate increase or no expression of p53,
respectively. Thus, the apoptotic responses observed in
the different oral cancer cell lines appeared to correlate
with the degree of p53 protein levels that were induced
upon Dicer1e depletion. Conversely, the cell cycle re-
sponse appeared to function independently of p53, based
on the fact that SCC-25 cells which lacked p53 were still
able to undergo cell cycle arrest upon Dicer1e silencing.
Down-regulation of Dicer1e sensitizes oral cancer cells
to cisplatin
Although several chemotherapeutic drugs, including cis-
platin, have proven effective in the treatment of head
and neck cancer [49-51], the failure of OSCCs to re-
spond to chemotherapeutic treatments due to acquiredFigure 7 Knockdown of Dicer1e enhances chemosensitivity
to cisplatin in oral cancer cells. The OSCC cell line SCC-25 was
transfected with either control non-targeting siRNA (siNT) or siRNA
targeting Dicer1e (siDicer1e). 24 hours post-transfection, 1.8 μM of
cisplatin (CDDP) was added and 48 hours later the cell viability was
assessed. Data are mean ± SEM of four independent experiments,
where *P < 0.05 and **P < 0.01 compared to cisplatin and siDicer1e
alone treated cells (Student’s t test).resistance limits the overall success of these types of
therapeutic strategies and in-part contributes to ~40% of
oral cancer-related patient deaths [5,52]. Therefore, to
assess whether the depletion of Dicer1e could contribute
towards the chemosensitization of oral cancer cells, we
transfected SCC-25 cells with either siNT or siDicer1e
24 hours prior to the addition of 1.8 μM (IC25) of cis-
platin for 48 hours. Of note, the IC25 value for cisplatin
in SCC-25 cells was determined from a cell viability plot
(Additional file 2: Figure S2). Analysis of cell viability be-
tween the different experimental treatments demon-
strated that Dicer1e silencing in combination with
cisplatin resulted in a significant reduction compared to
cisplatin or siDicer1e alone (Figure 7). Combination
treatments of siNT with cisplatin did not show any sta-
tistical differences in cell viability when compared with
cisplatin alone. These data suggested that the enhanced
response to cisplatin was associated with Dicer1e deple-
tion in oral cancer cells.
Discussion
The 93-kDa Dicer1e protein variant was first described
in a study by Hinkal et al. [36], where it was reported to
be differentially expressed in epithelial and mesenchymal
breast cancer cells. In our study, Dicer1e was similarly
found to be differentially expressed in oral cancer cells
and during EMT, with epithelial oral cancer cells exhibit-
ing higher levels of Dicer1e expression compared to cells
of mesenchymal phenotype. Moreover, Dicer1e protein
levels were found to be overexpressed in epithelial
OSCC cell lines and in OSCC tissues compared to nor-
mal HOKs and adjacent normal tissues, respectively.
Together, these data implied that the upregulation of
Dicer1e expression potentially contributes towards the
cellular transformation of normal oral epithelial cells
with expression decreasing upon EMT and the develop-
ment of more aggressive metastatic disease.
Although several studies had predicted that the 93-
kDa Dicer1e protein variant was the product of a Dicer1
mRNA variant based on information available through
the NCBI AceView database [23,36], our study is the
first to provide biochemical evidence for the existence of
the Dicer1e transcript (2,822 nucleotides) via our 5′ and
3′-RACE analyses. The Dicer1e transcript we identified
encoded an 820 amino acid truncated form of Dicer1
protein with a predicted M.W. of 93-kDa that comprised
both RNase III domains and the dsRBD. Interestingly,
the Dicer1e protein sequence was predicted to contain a
NLS (247 – 264 aa) and our subcellular fractionation
and IIF studies confirmed Dicer1e localization to the
nucleus. A recent study by Doyle et al. [41], however,
reported that this predicted NLS could not drive the nu-
clear localization of a reporter gene in HeLa cells. Instead,
the study found that the dsRBD of human Dicer1
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helicase domain was necessary to cause partial accumula-
tion of Dicer1 in the nucleus upon leptomycin B treat-
ment [41]. The significance of these findings is that
Dicer1e lacks the helicase domain, but retains the dsRBD
NLS which could account for its ability to localize to the
nucleus. In addition to its nuclear localization, we also
found Dicer1e to localize to the cytoplasm of several epi-
thelial cancer cell lines (CAL 27, SCC-4, and SCC-25),
where Dicer1e was found to be upregulated, and in trans-
fected HeLa cells overexpressing a recombinant form of
the Dicer1e protein. One possibility for this accumulation
in the cytoplasm could have been due to the saturation of
a nuclear transport system responsible for importing
Dicer1e into the nucleus. Another possibility is that high
expression levels of Dicer1e potentially perturbed its
RNA-binding status, and hence its subcellular localization.
Interestingly, the Doyle et al. study [41] found that when
the RNA-binding potential of the RNase III domains were
compromised within a C-terminal construct of Dicer1
(containing both RNase III domains plus dsRBD), a con-
struct structurally similar to Dicer1e, it caused the protein
to accumulate in the nucleus. Conversely, if one recalls,
the wild-type construct failed to localize to the nucleus
and instead accumulated in the cytoplasm, thus, sugges-
ting that associated RNAs were masking the dsRBD NLS
[41]. Consequently, the subcellular localization of Dicer1e
may in-part depend on its RNA-binding status, which has
the ability to mask/expose the dsRBD NLS and if dysregu-
lated could lead to mislocalization of the protein.
Due to the fact that Dicer1e protein was increased in
OSCC cell lines of epithelial phenotype and in OSCC
tissues, the biological consequence of Dicer1e in oral
cancer cells was examined, in particular its role in cell
proliferation and clonogenic potential. The transfection
of an exogenous siRNA targeting Dicer1e specifically,
but not Dicer1, significantly inhibited the proliferation
and clonogenic potential of three separate oral cancer
cell lines, by either inducing apoptosis and/or G2/M cell
cycle arrest. Moreover, the intensity of the apoptotic re-
sponse appeared to correlate with the levels of p53 pro-
tein induced upon Dicer1e depletion. Interestingly, p53
levels have been found to determine the extent of an
apoptotic response in cells [53,54]. Regardless, these data
demonstrated that Dicer1e contributes towards cancer
cell growth and that its downregulation induces cellular
stresses that result in either cell death and/or growth ar-
rest. Furthermore, because Dicer1e silencing affected cell
cycle kinetics, this suggested that its knockdown could
enhance the sensitivity of a cancer cell to the effects of a
DNA-damaging agent, such as cisplatin. In fact, in our
studies, we found that Dicer1e silencing could indeed
enhance the chemosensitivity of cancer cells to cisplatin,
thus, implying that targeting of Dicer1e could be aneffective strategy to sensitizing oral cancer cells to
chemotherapeutics.
Finally, it is interesting to note, that a report studying
the coordinated activities of human Dicer1 domains in
RNA processing found that a truncated construct of
Dicer1, termed hDcr-C, which is structurally similar to
Dicer1e, was capable of binding and cleaving both long
dsRNA and pre-miRNAs, with the binding/cleavage
being more active towards dsRNAs [55]. This is particu-
larly intriguing in light of the fact that a recently iden-
tified truncated form of Dicer1 in C. elegans termed,
sDCR-1, that shares the same domains as hDCr-C and
Dicer1e was found to enhance the exogenous RNAi
pathway via its calatytic activity, whereas its concurrent
role as a negative regulator of miRNA biogenesis func-
tioned independently of this activity [56]. The enhanced
exogenous RNAi response by sDCR-1 was postulated to
be due to the loss of the helicase domain [56], which has
been previously reported to have an autoinhibitory func-
tion that hinders the catalytic efficiency of human
Dicer1 in processing long dsRNAs [57]. In line with this,
a mouse oocyte-specific Dicer1 isoform lacking part of
the helicase domain was similarly found to be more effi-
cient at processing long dsRNA substrates compared to
the full-length form [58]. As a result, due to the fact that
Dicer1e shares the same domains as hDcr-C and sDCR-1,
there is a strong likelihood that Dicer1e will similarly ex-
hibit more activity towards the processing of perfectly
matched dsRNAs. However, one cannot exclude the possi-
bility that Dicer1e could also regulate miRNA biogenesis.
In fact, in recognizing the structural similarities between
sDCR-1 and Dicer1e, the Sawh and Duchaine study [56]
also ectopically expressed Dicer1e in human cells and
found that, similar to sDCR-1, it could modulate the bio-
genesis of specific miRNAs. Thus, based on these key
pieces of evidence, the possibility that Dicer1e could have
the ability to enzymatically process dsRNAs and modulate
miRNA-specific biogenesis differently than Dicer1 is pro-
mising. Consequently, further studies will investigate the
molecular function of Dicer1e in cells pertaining to RNAi/
miRNA biology and its relevance to cancer.
Conclusions
Our present study identified and characterized a 93-kDa
Dicer1 protein variant, Dicer1e, in oral cancer cells. In
particular, Dicer1e protein levels were found to be over-
expressed in OSCC cell lines of epithelial phenotype and in
OSCC tissues with its levels downregulated during EMT.
Moreover, Dicer1e was encoded by a ~3 kbp transcript and
was localized predominantly in the nucleus of both normal
and cancer cells. Transient transfection of a recombinant
form of Dicer1e also confirmed its localization within the
nucleus. However, cytoplasmic localization was also de-
tected in cancer cells exhibiting high levels of Dicer1e
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recombinant form of Dicer1e. Depletion of Dicer1e inhib-
ited the cell proliferation and clonogenic potential of oral
cancer cells by inducing either apoptosis and/or G2/M cell
cycle arrest. In addition, Dicer1e silencing chemosensitized
oral cancer cells to cisplatin treatment. Together, these data
imply that Dicer1e upregulation contributes to oral cancer
progression and that silencing its expression using RNAi
strategies could be potentially used in conjunction with




Human tongue SCC cell lines CAL 27, SCC-4, SCC-9,
SCC-15, and SCC-25 were purchased from American Type
Culture Collection (ATCC, Manassas, VA) and cultured in
ATCC-specified complete growth media. Normal HOKs
were obtained from ScienCell™ Research Laboratories
(Carlsbad, CA) and cultured in oral keratinocyte medium
supplemented with oral keratinocyte growth supplement
and penicillin/streptomycin solution (ScienCell™ Research
Laboratories). The HeLa cell line and the breast cancer cell
line T47D were kindly provided by Gunhild Sommer
(Medical University of South Carolina (MUSC)) and Yusuf
Hannun (Stony Brook University), respectively, and were
cultured in Dulbecco’s Modified Eagle Medium (Media-
tech, Inc., Manassas, VA) supplemented with 10% fetal bo-
vine serum (HyClone Laboratories Inc., Logan, Utah). All
cells were maintained in a 37°C incubator with 5% CO2.
To examine the effects of TGF-β treatment, SCC-4 and
SCC-25 cells were grown to 40% confluency, after which
they were serum-starved and then induced with TGF-β2
(a kind gift from Philip Howe (MUSC)), at 5 ng/ml for
8 days. Culture medium was changed every other day.
Western blot analysis
Proteins were extracted as described in Cantini et al., [59].
Between 5-20 μg of the cell lysates were then resolved in
Mini-PROTEAN® TGX™ Precast 10% or 4-15% gels (BIO-
RAD, Hercules, CA) and transferred to a PVDF membrane
(Millipore, Bedford, MA). The PVDF membrane was
blocked in 5% non-fat dried milk in Tris-HCl-buffered-
saline supplemented with 0.1% Tween-20 (TBS-T) for
2 hours at room temperature (RT). Afterwards, the mem-
brane was incubated overnight at 4°C with either of the
following primary antibodies: anti-Dicer1 (1:1,000, Abcam,
Cambridge, MA), an antibody also capable of detecting
Dicer1d/e [23,36], anti-E-cadherin (1:2,500, BD Biosciences,
San Jose, CA), anti-vimentin (1:1,000, Santa Cruz
Biotechnology, Santa Cruz, CA), anti-cleaved Caspase-3
(1:1,000, Cell Signaling Technology, Danvers, MA), anti-
GAPDH (1:10,000, Cell Signaling Technology), anti-
HDAC1 (1:10,000, Cell Signaling Technology), anti-β-actin(1:12,000, Sigma, Saint Louis, MO), anti-p53 (1:1,000,
Dako, Carpinteria, CA), and anti-PARP (1:1,000, Cell
Signaling Technology). Subsequently, the membranes were
washed four times with TBS-T and then incubated with the
corresponding secondary antibodies either horseradish pe-
roxidase-conjugated goat anti-mouse (1:2,000 or 1:20,000)
or anti-rabbit IgG (1:2,000 or 1:20,000, SouthernBiotech,
Birmingham, AL) for 1 hour at RT. Immunoreactive bands
were detected with the SuperSignal Chemiluminescent sys-
tem (Thermo Fisher Scientific, Waltham, MA), according
to the manufacturer’s instructions. Quantitative determina-
tions were performed by densitometry of the corresponding
non-saturated band intensities, normalized against the re-
spective intensities of GAPDH using ImageJ software [60].
Human tissue extracts
Frozen human tongue SCC tissue with adjacent normal
tissue samples were obtained from the MUSC Hollings
Cancer Center (HCC) Biorepository & Tissue Analysis
Shared Resource. The study was approved by the ethics
committee of the MUSC Institutional Review Board.
Patients’ identities associated with all the tissue samples
were removed prior to analyses. After procurement of
the tissues, the samples were homogenized with stainless
steel blend beads (Next Advance, Averill Park, NY) in lysis
buffer containing 100 mM Tris-HCl, pH 7.4, 2% SDS, and
1× protease inhibitor cocktail (Thermo Fisher Scientific)
using a Next Advance Bullet Blender®, according to the
manufacturer’s instructions. Afterwards, 10 μg of protein
extracts were used for Western blot analysis.
RNA extraction and 5′-RACE
SCC-25 cells were used to isolate mRNA with the
FastTrack® 2.0 kit (Life Technologies, Grand Island, NY),
following the manufacturer’s protocol. Once purified,
250 ng of the mRNA were then used to perform 5′-RACE
with the GeneRacer® kit (Life Technologies) following
the manufacturer’s instructions. Briefly, the mRNA was
dephosphorylated and decapped before an RNA oligo of
known sequence was ligated to the 5′-end. Subsequently,
a reverse transcription reaction was carried out using an
oligo dT primer. Afterwards, PCR amplification was
performed using the kit’s GeneRacer 5′-sense primer
(GR5S) and a custom made Dicer1e-specific antisense pri-
mer (Dic1e5AS, 5′-TTCAGCTAAAATCCGCAGGAAG
TGAT-3′). The PCR parameters used were as follows:
94°C for 2 minutes (1 cycle); 94°C for 30 seconds and
72°C for 3 minutes (5 cycles); 94°C for 30 seconds and
70°C for 3 minutes (5 cycles); 94°C for 30 seconds, 66°C
for 30 seconds, and 68°C for 3 minutes (25 cycles); 68°C
for 10 minutes (1 cycle). After PCR, the amplification
product was electrophoresed on a 2% agarose gel and the
predicted PCR band was gel purified using the QIAquick®
PCR Purification kit (Qiagen, Valencia, CA). A second
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primers to increase the PCR fragment copy number in
order to facilitate cloning using the TOPO® TA Cloning®
kit (Life Technologies). Colonies were screened for insert
by restriction enzyme digestion, after which purified
plasmid DNAs from positive colonies were sent for
sequencing.
3′-RACE
50 ng of purified mRNA from SCC-25 cells was used to
perform 3′-RACE with the FirstChoice® RLM-RACE kit
(Life Technologies), following the manufacturer’s protocol.
Briefly, a reverse transcription reaction was carried out
with the kit’s 3′-RACE Adapter containing a string of T
residues to prime the reaction. Afterwards, PCR was
carried out with the kit specific 3′-RACE outer antisense
primer and a Dicer1/1e-specific sense primer, (Dic1/
1e3S1, 5′-GGTTCCAGAACTCTGTGCTA-3′). The PCR
parameters used were as follows: 94°C for 5 minutes
(1 cycle); 94°C for 45 seconds, 60°C for 30 seconds, 72°C
for 45 seconds (35 cycles); 72°C for 7 minutes (1 cycle).
Subsequently, a nested PCR was performed with 1 μl of
initial PCR product, using the kit’s 3′-RACE inner anti-
sense primer and a nested Dicer1e-specific sense primer
(Dic1e3S2, 5′-CACTTCCTGCGGATTTTAGCTGAA-3′).
The same PCR parameters were used as for the initial
PCR. After the nested PCR, the amplification product was
gel purified and cloned, as described above, after which
purified plasmid DNAs from positive colonies were sent
for sequencing.
DNA sequencing
Sequencing was performed by Eurofins MWG Operon
(Huntsville, AL). M13 forward and reverse primers were
used to sequence the complete sense and antisense
strands of the 5′-RACE product and part of the 3′-RACE
product. An additional series of sequencing primers were
designed to sequence the complete sense and antisense
strands of the 3′-RACE product. For the sense strand the
primers used were: F-SeqII, 5′-CCTTTTTAAAGCAT
GCCATC-3′; F-SeqIII, 5′-AGCAGTCCATTTCTTAC
GAC-3′; and F-SeqIV, 5′-TCTCTCCTGAGCTCTTC
CAT-3′. For the antisense strand the primers used were:
R-SeqII, 5′-ATGGAAGAGCTCAGGAGAGA-3′; R-SeqIII,
5′-GTCGTAAGAAATGGACTGCT-3′; and R-SeqIV, 5′-
GATGGCATGCTTTAAAAAGG-3′. Upon receiving the
sequencing data, Vector NTI® (Life Technologies) software
was used to assemble contigs in order to obtain the
complete Dicer1e sequence.
Custom gene synthesis and cloning
After verifying the Dicer1e sequence, the gene was custom
synthesized by GenScript (Piscataway, NJ) from the start
to stop codons with NotI and ApaI restriction sites added5′ and 3′ relative to each codon, respectively. The full-
length gene was then cloned by GenScript into the EcoRV
site within the pUC57 plasmid vector, after which it was
subsequently subcloned in-frame into pGen2.1, a mam-
malian N-terminal FLAG-tag gene expression vector,
using the NotI and ApaI restriction sites. All constructs
were verified by DNA sequencing. Upon receiving the the
pGen2.1-Dicer1e plasmid construct, the contruct was
transformed into NEB 5-α competent E. coli cells (New
England BioLabs, Ipswich, MA) and purified for trans-
fection purposes using the EndoFree® Plasmid Maxi kit
(Qiagen).
Biochemical fractionation
HOK and OSCC cell lines were plated onto 6-cm dishes
and grown to 80% confluency. Afterwards, the cells were
trypsinized, centrifuged at 500 × g for 5 minutes, washed
with ice-cold 1× PBS and then centrifuged again. Cyto-
plasmic and nuclear extracts were obtained from the cell
pellets using the NE-PER® kit (Thermo Fisher Scientific),
according to the manufacturer’s instructions. 4.5 μg of
cytoplasmic and nuclear protein extracts were used for
Western blot analysis.
Plasmid transfections and immunofluorescence
The pGen2.1-Dicer1e plasmid construct was transiently
tranfected into HeLa cells grown on Collagen Type I coated
8-chamber slides (BD Biosciences) using Lipofectamine®
2000 (Life Technologies), according to the manufacturer’s
recommendation. 24 hours post-transfection the cells
were processed for indirect immunofluorescence as pre-
viously described [59] using anti-FLAG® M2 antibody
(1:100, Sigma). Alexa Fluor® 488-conjugated goat anti-
mouse IgG (1:400, Life Technologies) was used as the cor-
responding secondary antibody. Images were obtained
using a Zeiss (Thornwood, NY) Axio Observer.D1 micro-
scope equipped with a LD A-Plan × 20/0.3 Ph1 objective.
siRNAs and transfections
The control siGENOME Non-Targeting siRNA #5 (siNT)
and the siRNA targeting the unique sequence of Dicer1e
(siDicer1e, sense: 5′-CCUGCGGAUUUUAGCUGAAd
TdT-3′, antisense: 5′-UUCAGCUAAAAUCCGCAGGd
TdT -3′) were synthesized by Thermo Fisher Scientific
Dharmacon (Lafayette, CO). Unless specified differently,
50 nM of either control siNT or siDicer1e were transiently
transfected into CAL 27, SCC-4, and SCC-25 cells using
INTERFERin® (Polyplus-transfection, New York, NY), ac-
cording to the manufacturer’s recommendations.
Cell proliferation assay
Cell proliferation was determined using the CyQUANT®
Cell Proliferation Assay Kit (Life Technologies). Briefly,
100,000 cells were seeded on 12-well plates one day prior
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fected with either control siNT or siDicer1e. 24 hours
post-transfection, 1000 cells were re-seeded onto black
96-well plates with clear bottom and then 2, 4, and 7 days
post-transfection the number of cells were assayed, ac-
cording to the manufacturer’s instructions. Fluorescence
at 480/520 nm was measured using a BioTek (Winooski,
VT) Synergy HT plate reader.
Colony formation assay
24 hours post-treatment with the specified siRNAs, the
OSCC cell lines were reseeded at 500 or 1,000 cells per
well on 6-well plates. After eleven days of incubation,
the cells were fixed in an acetic acid:methanol solution
(1:7 ratio), and then stained with Giemsa. Colonies with
more than 50 cells were counted.
Flow cytometry
Cell cycle analysis was determined by analyzing the
DNA content of the cells using propidium iodide (PI), as
described by Calipel et al. [61] with only minor modifi-
cations. Briefly, 48 hours post-treatment, the cells were
trypsinized, washed in 1× PBS, and then fixed in ice-
cold 70% ethanol at 4°C overnight. Afterwards, the cells
were rehydrated in ice-cold 1× PBS, centrifuged at 500 × g
for 5 minutes, resuspended in 0.5 ml of PI/RNase Staining
Solution (Cell Signaling Technology), and stained at 4°C
for at least 2 hours. Flow cytometric analyses of the sam-
ples were then performed using a BD FACSCalibur Ana-
lytical Flow Cytometer available through the MUSC HCC
Flow Cytometry & Cell Sorting Shared Resource. Data
analyses were performed using ModFit LT software.
Drug sensitivity assay
The drug sensitivity was determined using the CellTiter 96®
AQueous One Solution Cell Proliferation Assay (Promega,
Madison, WI). Briefly, 3,000 cells were seeded on 96-well
plates one day prior to treatment. Afterwards, the cells
were transiently transfected with 25 nM of either control
siNT or siDicer1e. 24 hours post-transfection, the treat-
ment was removed and fresh culture medium containing
1.8 μM of cisplatin was added (Sigma). 48 h post-trea-
tment with cisplatin the cell viability was assayed, accor-
ding to the manufacturer’s instructions. Absorbance at
490 nm was measured using a BioTek Synergy HT plate
reader.
Statistical analysis
The results from three or four independent experiments
performed in either duplicate or triplicate were presented
as mean ± SEM. Student’s t test was used for statistical
evaluation. Statistical analyses were performed using
GraphPad Prism 6 software (La Jolla, CA).Additional files
Additional file 1: Figure S1. Assessment of long-term Dicer1e silencing
in oral cancer cells. Western blot analysis of Dicer1 and Dicer1e protein
levels in human OSCC cell lines (CAL 27, SCC-4, and SCC-25) 7 and 9 days
post-transfection with either control non-targeting siRNA (siNT) or siRNA
targeting Dicer1e (siDicer1e). β-actin was used as a loading control.
Additional file 2: Figure S2. Dose response of SCC-25 oral cancer cells
to cisplatin. Cells were treated with increasing concentrations of cisplatin
(ranging from 0.001 to 30 μM), after which cell viability was assayed
48 hours post-treatment. Data are mean ± SEM of three independent
experiments.
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